Dr. Zsuzsanna Nagy of the University of Birmingham presented data from a clinical study, funded by Cytox Limited, demonstrating that a simple bloodbased biomarker discriminated between patients with Alzheimers disease (AD) and control subjects. The findings were statistically highly significant, and the test discriminated between the two groups with 80% sensitivity and 80% specificity. The [...]

Rexahn Pharmaceuticals, Inc. (NYSE Amex RNN), announced the results of a wideranging animal study offering more evidence that Serdaxin™ may be an effective therapeutic for the treatment of anxiety disorders in humans. Serdaxin is Rexahns leading anxiety and depression drug candidate, and is currently in Phase II clinical trials.
The research tested Clavulanic acid, the [...]